{
    "clinical_study": {
        "@rank": "139549", 
        "arm_group": [
            {
                "arm_group_label": "Dosing Regimen 1", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous injection"
            }, 
            {
                "arm_group_label": "Active Comparator", 
                "arm_group_type": "Active Comparator", 
                "description": "Subcutaneous injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subcutaneous injection"
            }, 
            {
                "arm_group_label": "Dosing Regimen 2", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This withdrawn study was to assess the safety and efficacy of secukinumab compared to\n      etanercept and placebo in patients who have moderate to severe, chronic, plaque-type\n      psoriasis."
        }, 
        "brief_title": "Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic plaque-type psoriasis, moderate to severe\n\n          -  Candidate for systemic therapy defined as having psoriasis not adequately controlled\n             by: topical treatment, phototherapy and/or previous systemic therapy\n\n        Exclusion Criteria:\n\n          -  Forms of psoriasis other than chronic plaque-type\n\n          -  Ongoing use of treatments not allowed for psoriasis\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900782", 
            "org_study_id": "CAIN457A2314", 
            "secondary_id": "2013-000463-83"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dosing Regimen 1", 
                    "Dosing Regimen 2"
                ], 
                "description": "Prefilled syringe.", 
                "intervention_name": "Intervention A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Active Comparator", 
                "description": "Prefilled syringe.", 
                "intervention_name": "Intervention B", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Prefilled syringe to match experimental drug and active comparator.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 14, 2013", 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Double-dummy, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis.", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PASI (psoriasis area and severity index) and IGA (investigator's global assessment)", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900782"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PASI (psoriasis area and severity index) and IGA (investigator's global assessment)", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "Vital signs, laboratory values, electrocardiograms (ECG), adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Week 12 and 52"
            }, 
            {
                "measure": "Patient reported outcome questionnaires", 
                "safety_issue": "No", 
                "time_frame": "Week 12 and 52"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}